Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.415 USD | +6.72% |
|
+20.74% | -40.37% |
07-11 | KeyBanc Adjusts Price Target on AbCellera Biologics to $5 From $7, Maintains Overweight Rating | MT |
06-13 | AbCellera Biologics Inc. Approves Election of Andrew Lo as Class I Director | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.37% | 941M | |
+25.20% | 46.56B | |
+45.38% | 41.67B | |
+0.18% | 41.16B | |
+33.32% | 32.4B | |
+20.77% | 28.18B | |
-6.35% | 28.1B | |
+48.78% | 14.52B | |
+47.45% | 13.74B | |
+3.13% | 12.17B |
- Stock Market
- Equities
- ABCL Stock
- News AbCellera Biologics Inc.
- KeyBanc Adjusts Price Target on AbCellera Biologics to $5 From $7, Maintains Overweight Rating